German diagnostics company SphingoTec GmbH (Hennigsdorf) and bestbion dx GmbH (Cologne) have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test…
A study on centenarians links sphingotec’s biomarker bio-Adrenomedullin (bio-ADM) to longevity. Human longevity has been previously linked by researchers to genetic factors, calorie restriction, and…
New research identifies blood biomarker as decisive link between fat intake and risk for cardiovascular disesases, diabetes and obesity; spingotec‘s revolutionary sphingotest®pro-NT test measures…
sphingotec, LLC, predictive diagnostic tests for cancer, cardiovascular diseases and kidney function, today announced the results of a survey gauging women’s understanding of breast cancer risk…
sphingotec LLC announced today that the results of two studies examining the association between proenkephalin (pro-ENK) and incident breast cancer were published online in the Journal of Clinical…
sphingotec, LLC, a developer of predictive diagnostic tests for cancer, cardiovascular diseases and kidney function, today announced the results of a survey gauging women’s understanding of breast…
Biotech company to present how biomarkers improve breast cancer risk prediction in women under hormone replacement therapy. Cambridge, Mass. – Feb. 4, 2015 – sphingotec LLC announced today that the…
SphingoTec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, today announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and…
